"Cyclophosphamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
| Descriptor ID |
D003520
|
| MeSH Number(s) |
D02.455.526.728.650.730.243 D02.705.672.500.243
|
| Concept/Terms |
Cyclophosphamide- Cyclophosphamide
- Cytophosphane
- Cyclophosphamide Monohydrate
- Monohydrate, Cyclophosphamide
- Cyclophosphane
|
Below are MeSH descriptors whose meaning is more general than "Cyclophosphamide".
Below are MeSH descriptors whose meaning is more specific than "Cyclophosphamide".
This graph shows the total number of publications written about "Cyclophosphamide" by people in this website by year, and whether "Cyclophosphamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclophosphamide" by people in Profiles.
-
Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL. J Magn Reson Imaging. 2019 12; 50(6):1742-1753.
-
The role of IL-1ß and TNF-a signaling in the genesis of cancer treatment related symptoms (CTRS): a study using cytokine receptor-deficient mice. Brain Behav Immun. 2014 May; 38:66-76.
-
Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996 Jul; 14(7):1982-92.
-
The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project. Am J Clin Oncol. 1994 Oct; 17(5):374-81; discussion 382.
-
Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry. 1991 Dec; 54(12):1055-60.
-
Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990 Jun; 8(6):1005-18.
-
Cyclophosphamide plus 5-FU versus 5-FU alone in advanced gastric carcinoma. Oncology. 1985; 42(3):141-3.